{"entity":{"id":"nct06203210","kind":"trial","name":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial in which amrubicin is one of the standard comparator treatments, run by Daiichi Sankyo in small-cell lung cancer, now recruiting.","summary":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06203210 by Daiichi Sankyo, with 540 participants planned, started 2024-05-21. Conditions listed: Small Cell Lung Cancer. Amrubicin is a comparator arm, not the drug under test. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06203210","url":"https://clinicaltrials.gov/study/NCT06203210"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["amrubicin"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06203210","phase":"3","setting":"A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)","sponsor":"Daiichi Sankyo","enrolled":540,"outcomes":[]},"route":"/trials/nct06203210/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}